Skip to main content
    O

    Oruka Therapeutics, Inc. (ORKA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $99.24
    -6.11 (-5.80%)

    Market Cap: $7.15B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Oruka Therapeutics, Inc. (ORKA) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Oruka Therapeutics (ORKA) to earn -$2.45 per share in the fiscal year ending Dec 31, 2026. Of 13 analysts, 13 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 8 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 1.85, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy215.4%
    Buy1184.6%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    13

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss.

    Fiscal year ending Dec 31, 2026
    -$2.45
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$2.95
    EPS consensus
    Next report
    Mar 10, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$2.45-$2.66 to -$2.077
    Dec 31, 2027-$2.95-$4.09 to -$2.149

    Quarterly Estimates

    The EPS consensus falls from -$0.69 for the quarter ending Dec 31, 2026 to -$0.73 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.69-$0.98 to -$0.3814
    Mar 31, 2027-$0.73-$0.88 to -$0.605

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 5 upward and 18 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202618
    Fiscal year ending Dec 31, 202736
    Quarter ending Mar 31, 202714

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$2.28.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$2.45-$2.37-$2.37-$2.37-$2.28N/A
    Fiscal year ending Dec 31, 2027-$2.95-$2.86-$2.86-$2.86-$2.77N/A
    Quarter ending Mar 31, 2027-$0.73-$0.72-$0.72-$0.72-$0.68N/A

    Frequently Asked Questions About ORKA

    What is the ORKA stock forecast?

    Consensus analyst estimates put Oruka Therapeutics's EPS at -$2.45 for the fiscal year ending Dec 31, 2026. The consensus rating from 13 analysts is Buy.

    How do analysts rate ORKA stock?

    Of 13 analysts covering Oruka Therapeutics, 2 rate it Strong Buy, 11 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from ORKA next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.45, with estimates from -$2.66 to -$2.07 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.95, with estimates from -$4.09 to -$2.14 from 9 analysts.

    How many analysts cover ORKA?

    13 analysts rate Oruka Therapeutics stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.